CN111089915A - Method for measuring concentration of docetaxel drug in human plasma - Google Patents
Method for measuring concentration of docetaxel drug in human plasma Download PDFInfo
- Publication number
- CN111089915A CN111089915A CN201911117108.8A CN201911117108A CN111089915A CN 111089915 A CN111089915 A CN 111089915A CN 201911117108 A CN201911117108 A CN 201911117108A CN 111089915 A CN111089915 A CN 111089915A
- Authority
- CN
- China
- Prior art keywords
- standard
- docetaxel
- concentration
- internal standard
- detected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/36—Control of physical parameters of the fluid carrier in high pressure liquid systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
Abstract
The invention discloses the technical field of a clinical blood concentration determination method of an anti-tumor drug, and particularly relates to a method for determining the concentration of a docetaxel drug in human plasma, wherein the detection method comprises the following steps: the method comprises the following steps of preparing a standard working solution, preparing an internal standard working solution, centrifuging detection blood, treating a sample to be detected and determining the sample to be detected, wherein the high-performance liquid chromatography tandem mass spectrometry is used for determining the blood concentration, and has high sensitivity, strong specificity and good repeatability; the analysis time is 3.5min by selecting and limiting the conditions of the high performance liquid chromatography-tandem mass spectrometry, the analysis time is greatly shortened, the use amount of an organic solvent is reduced, the pollution to the environment is further reduced, and the lowest quantitative lower limit is reduced.
Description
Technical Field
The invention relates to the technical field of a clinical blood concentration determination method of an anti-tumor drug, in particular to a method for determining the concentration of a docetaxel drug in human plasma.
Background
Docetaxel is an antimetabolite antitumor drug, is clinically suitable for advanced or metastatic breast cancer with failure of advanced chemotherapy, and docetaxel is also suitable for treatment of advanced or metastatic non-small cell lung cancer with failure of chemotherapy mainly based on cisplatin. Because the metabolic process in vivo has larger individual difference, the blood concentration in vivo is closely related to clinical curative effect and adverse reaction, the blood concentration is detected so as to adjust the dosage and reduce the adverse reaction, and the method has great significance in clinical medication.
The conventional methods for measuring the blood concentration of docetaxel are few, and mainly comprise a high performance liquid chromatography method and a liquid chromatography tandem mass spectrometry method. The prior high performance liquid chromatography has the problems of complex pretreatment and large minimum quantitative lower limit, for example, in an article for measuring the concentration of docetaxel in human plasma by an HPLC method from China journal of clinical pharmacy, the problem that the quantitative lower limit of the method for measuring the concentration of docetaxel in human plasma by the high performance liquid chromatography is 0.064mg/mL, the analysis time is long, the sample injection time is 8min, a large amount of organic solvent is consumed and the like is pointed out. The known liquid chromatography tandem mass spectrometry adopts animal samples, and has large difference with human samples.
Disclosure of Invention
The invention aims to provide a method for determining the concentration of docetaxel in human plasma, which adopts a high performance liquid chromatography-tandem mass spectrometry method and combines an internal standard method and the high performance liquid chromatography-tandem mass spectrometry method to establish a method for rapidly and sensitively determining the concentration of docetaxel in human plasma so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a method for determining the concentration of a docetaxel medicament in human plasma adopts high performance liquid chromatography-tandem mass spectrometry for detection, and the detection method comprises the following steps:
step 1: preparation of standard working solution
Accurately weighing docetaxel standard, placing the docetaxel standard in a centrifuge tube, dissolving the docetaxel standard in pure methanol to prepare a standard stock solution S1, diluting the standard stock solution S1 with a methanol aqueous solution to prepare a plurality of standard working solutions, and freezing and storing the standard working solutions;
step 2: preparation of internal standard working solution
Accurately weighing a docetaxel-D9 standard substance, placing the docetaxel-D9 standard substance in a centrifuge tube, dissolving the docetaxel-D9 standard substance in pure methanol to prepare a standard stock solution S2, diluting the standard stock solution S2 with a methanol aqueous solution to obtain an internal standard working solution, and freezing and storing the internal standard working solution;
and step 3: centrifugation for testing blood
Taking a blood sample to be detected, carrying out centrifugal separation operation, taking supernatant to obtain plasma, and freezing and storing the plasma for later use before analysis;
and 4, step 4: treatment of samples to be tested
A. Transferring the internal standard working solution obtained in the step 2 into a centrifuge tube by using a liquid transfer gun, adding the plasma obtained in the step 3, and mixing in a vortex oscillation mode;
B. transferring the extracting agent by using a liquid transfer gun, adding the extracting agent into the centrifugal tube in the step A, mixing in a vortex oscillation mode, and then carrying out centrifugal separation operation to obtain supernatant;
C. transferring the supernatant liquid in the step B into a centrifugal tube by using a liquid transfer gun, drying by using nitrogen, adding a methanol aqueous solution, mixing in a vortex oscillation mode, and then carrying out centrifugal separation operation to obtain a supernatant liquid, wherein the obtained supernatant liquid is a sample to be detected;
and 5: determination of samples
D. Drawing of standard curve
Firstly, the standard working solution with different concentrations in the step 1 is respectively mixed with blank plasma of a normal person to prepare standard working blood, processing according to the step 4, detecting the obtained standard curve sample to obtain docetaxel and internal standard chromatograms of different standard curve samples, respectively obtaining the peak area of a standard target substance and the peak area of an internal standard substance in a chromatogram, taking the ratio of the peak area of the standard target substance to the peak area of the internal standard substance as the ordinate y of a standard curve chart, taking the ratio of the blood concentration of a target substance to be detected in blood plasma and the concentration of an internal standard working solution after the standard working solution is prepared, namely the relative concentration of docetaxel, as the abscissa x of a standard curve graph, performing linear regression on the detection data by a weighted least square method to obtain a standard curve equation of y ═ a × x + b, and obtaining weight coefficients a and b;
E. determination of samples to be tested
And (3) detecting the sample to be detected in the step (C) by using a high performance liquid chromatography-tandem mass spectrometry analyzer to obtain a docetaxel and internal standard chromatogram of the sample to be detected, obtaining the peak area of a target object to be detected and the peak area of an internal standard object in the chromatogram, calculating the ratio y of the peak area of the target object to be detected and the peak area of the internal standard object, and substituting the ratio y into a standard curve equation in the step (D) to calculate the relative concentration x of the docetaxel.
The conditions of the high performance liquid chromatography-tandem mass spectrometry are as follows: performing gradient elution by using a proshell 120 EC-C18 chromatographic column (3.0 x 50mm, 2.7 mu m), wherein the column temperature is 30 ℃, the mobile phase A is 1mmol/L ammonium formate water, the mobile phase B is pure acetonitrile, the flow rate is 0.4mL/min, the sample introduction amount is 5 mu L, and the analysis time is 3.5 min; the mass spectrum is measured by adopting an electrospray ion source and selecting a mass spectrum scanning mode of a multi-reaction detection mode under a positive ion ionization mode, wherein the docetaxel and internal standard docetaxel-D9 parent ions are 808.30 and 817.30 respectively, daughter ions are 527.1 and 227.2 respectively, and the retention time is 2.24 and 2.23min respectively.
Preferably, the number of the standard working solutions prepared in step 1 is 8.
Preferably, the 8 standard working solutions are docetaxel solutions with the concentration of 40ng/mL, 100ng/mL, 200ng/mL, 500ng/mL, 1000ng/mL, 2000ng/mL, 10000ng/mL and 20000ng/mL respectively.
Preferably, the methanol aqueous solution in step 1, step 2 and step 4C is composed of methanol and water, and the mass ratio of the methanol aqueous solution to the water is 1: 1.
The invention has the beneficial effects that: a method for determining the concentration of docetaxel in human plasma comprises the steps of selecting and limiting conditions of high performance liquid chromatography-tandem mass spectrometry, adopting a shell 120 EC-C18 chromatographic column (3.0 x 50mm, 2.7 mu m), carrying out gradient elution by using a mobile phase A of 1mmol/L ammonium formate water and a mobile phase B of pure acetonitrile at the temperature of 30 ℃, wherein the flow rate is 0.4mL/min, and the sample injection amount is 5 mu L, so that the analysis time is shortened to 3.5 min; the mass spectrum is measured by adopting an electrospray ion source and selecting a mass spectrum scanning mode of a multi-reaction detection mode under a positive ion ionization mode, wherein the docetaxel and internal standard docetaxel-D9 parent ions are 808.30 and 817.30 respectively, daughter ions are 527.1 and 227.2 respectively, and the retention time is 2.24 and 2.23min respectively.
The method for determining the blood concentration by the liquid high performance chromatography-tandem mass spectrometry has high sensitivity, strong specificity and good reproducibility; the analysis time is greatly shortened, and the use amount of an organic solvent is reduced, so that the pollution to the environment is reduced; the lowest quantitative lower limit is lowered.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
Example (b):
step 1: preparation of standard working solution
Accurately weighing 2.52mg of a docetaxel standard, placing the docetaxel standard in a 5mL centrifuge tube, precisely transferring a pure methanol solution for dissolving to obtain a standard stock solution S1, namely a docetaxel solution with the concentration of 1mg/mL, diluting the standard stock solution A with a methanol-water (1:1) solution, respectively preparing 8 standard working solutions with the concentrations of 40-20000ng/mL docetaxel, respectively 40ng/mL, 100ng/mL, 200ng/mL, 500ng/mL, 1000ng/mL, 2000ng/mL, 10000ng/mL and 20000ng/mL, and storing at-80 ℃;
step 2: preparation of internal standard working solution
Accurately weighing 2.85mg of a docetaxel-D9 standard substance, placing the docetaxel-D9 standard substance in a 5mL centrifuge tube, precisely transferring a pure methanol solution for dissolving to obtain a standard stock solution S2, namely a docetaxel-D9 solution with the concentration of 1mg/mL, diluting the standard stock solution S2 with a methanol-water solution (1:1) to obtain an internal standard working solution with the concentration of 500ng/mL, and storing at-80 ℃;
and step 3: centrifugation for testing blood
Centrifuging at least 2mL of blood to be detected at a centrifugal speed of 3500rpm for 10min, collecting supernatant to obtain plasma, and freezing the plasma at-20 deg.C for storage until the plasma is ready for analysis;
and 4, step 4: processing of samples to be tested
A. Transferring 10 mu L of the internal standard working solution prepared in the step 2 into a 1.5mL centrifugal tube by using a liquid transfer gun, adding 50 mu L of the plasma prepared in the step 3, and mixing for 3min by vortex oscillation at the rotating speed of 1500 rpm;
B. transferring 1.0mL of methyl tert-butyl ether by using a liquid transfer gun, adding into the centrifuge tube of A, mixing for 3min by vortex oscillation at the rotating speed of 1500rpm, and centrifuging for 5min at the rotating speed of 14000rpm to obtain supernatant;
C. transferring 900 mu L of the supernatant in the B into a 1.5mL centrifuge tube by using a liquid transfer gun, drying by using nitrogen, adding 100 mu L of methanol-water solution (1:1), mixing for 3min by vortex oscillation at the rotating speed of 1500rpm, and centrifuging for 5min at a high speed at the rotating speed of 14000rpm to obtain the supernatant which is the sample to be detected;
and 5: determination of samples
D. Drawing of standard curve
Firstly, 10 mu L of 8 standard working solutions with different concentrations in the step 1 are respectively mixed with 190 mu L of blank plasma of a normal person to prepare standard working blood, processing according to the steps in the step 4, detecting the obtained standard curve sample in an instrument to obtain docetaxel and an internal standard chromatogram of the 8 standard solutions, respectively obtaining the peak area of a standard target substance and the peak area of an internal standard substance in a chromatogram, taking the ratio of the peak area of the standard target substance to the peak area of the internal standard substance as the ordinate y of a standard curve chart, taking the ratio of the blood concentration of the target substance to be detected in the plasma and the concentration of the internal standard working solution, namely the relative concentration, after the standard working solution is prepared as the abscissa x of a standard curve graph, wherein the data are shown in table 1, performing linear regression on the detection data by a weighted least square method to obtain a standard curve equation of which y is 0.0055 x + 0.000449.
TABLE 1 Linear relationship related data
| Name of sample introduction | Peak surface of object to be measured | Peak area of internal standard | y value | Blood concentration of the drug to be measured | Concentration of internal standard | Value of x |
| sd1_01 | 622 | 55263 | 0.011 | 2 | 500 | 0.08 |
| sd2_01 | 1493 | 60457 | 0.025 | 5 | 500 | 0.20 |
| sd3_01 | 3601 | 59049 | 0.061 | 10 | 500 | 0.40 |
| sd4_01 | 8104 | 61149 | 0.133 | 25 | 500 | 1.0 |
| sd5_01 | 17760 | 57504 | 0.309 | 50 | 500 | 2.0 |
| sd6_01 | 31707 | 58906 | 0.538 | 100 | 500 | 4.0 |
| sd7_01 | 153473 | 63580 | 2.414 | 500 | 500 | 20 |
| Sd8_01 | 306487 | 54296 | 5.645 | 1000 | 500 | 40 |
E. Determination of samples to be tested
And (3) monitoring the sample to be detected in the step (C) by using a high performance liquid chromatography tandem mass spectrometry analyzer to obtain the docetaxel and an internal standard chromatogram of the sample to be detected, obtaining the ratio y of the peak area of a target object to be detected and the peak area of the internal standard in the docetaxel and internal standard chromatogram, substituting the ratio y into a standard curve equation in the step (D), obtaining the relative concentration x of the docetaxel in the object to be detected by calculation, wherein the concentration of the internal standard working solution is known, and thus calculating the concentration of the docetaxel in the object to be detected.
The conditions of the high performance liquid chromatography-tandem mass spectrometry are as follows:
a proshell 120 EC-C18 column (3.0 x 50mm, 2.7 μm) was used; the column temperature was 30 ℃. The mobile phase A is 1mmol/L ammonium formate water, and the mobile phase B is pure acetonitrile for gradient elution. The flow rate is 0.4mL/min, the sample size is 5 μ L, and the analysis time is 3.5 min.
The gradient elution procedure was as follows:
the mass spectrum is measured by adopting an electrospray ion source and selecting a mass spectrum scanning mode of a multi-reaction detection mode under a positive ion ionization mode, wherein the docetaxel and internal standard docetaxel-D9 parent ions are 808.30 and 817.30 respectively, daughter ions are 527.1 and 227.2 respectively, and the retention time is 2.24 and 2.23min respectively.
Firstly, methodology verification:
linear relationship and quantitative limits of the method
The standard curve was obtained by the method described above in D, and the results showed that the linear range and quantitative limit of docetaxel were as follows:
(1) limit of quantitation (LOQ): 2 ng/mL.
(2) Linear range: the docetaxel has good linearity and a correlation coefficient R in the range of 2ng/mL to 1000ng/mL2>0.99。
Second, the recovery rate and precision of the method
Docetaxel stock solution is prepared into high, medium and low concentrations of 3 to carry out recovery rate and precision experiments, pretreatment and measurement are carried out according to the embodiment, 3 batches are repeatedly measured, and the recovery rate and the precision are shown in the following table 2. The average recovery rate of the high, medium and low concentration levels is 91.5 to 92.7 percent, and the relative standard deviation is 2.75 to 6.95 percent.
TABLE 2 recovery and precision of docetaxel
By combining the verification experiments, the recovery rate, the precision and other technical indexes of the method meet the requirements, and the method for detecting the concentration of the docetaxel in blood has the advantages of good reproducibility, high recovery rate and high detection accuracy.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (4)
1. A method for determining the concentration of docetaxel in human plasma adopts high performance liquid chromatography-tandem mass spectrometry for detection, and is characterized in that: the detection method comprises the following steps:
step 1: preparation of standard working solution
Accurately weighing docetaxel standard, placing the docetaxel standard in a centrifuge tube, dissolving the docetaxel standard in pure methanol to prepare a standard stock solution S1, diluting the standard stock solution S1 with a methanol aqueous solution to prepare a plurality of standard working solutions, and freezing and storing the standard working solutions;
step 2: preparation of internal standard working solution
Accurately weighing a docetaxel-D9 standard substance, placing the docetaxel-D9 standard substance in a centrifuge tube, dissolving the docetaxel-D9 standard substance in pure methanol to prepare a standard stock solution S2, diluting the standard stock solution S2 with a methanol aqueous solution to obtain an internal standard working solution, and freezing and storing the internal standard working solution;
and step 3: centrifugation for testing blood
Taking a blood sample to be detected, carrying out centrifugal separation operation, taking supernatant to obtain plasma, and freezing and storing the plasma for later use before analysis;
and 4, step 4: treatment of samples to be tested
A. Transferring the internal standard working solution obtained in the step 2 into a centrifuge tube by using a liquid transfer gun, adding the plasma obtained in the step 3, and mixing in a vortex oscillation mode;
B. transferring the extracting agent by using a liquid transfer gun, adding the extracting agent into the centrifugal tube in the step A, mixing in a vortex oscillation mode, and then carrying out centrifugal separation operation to obtain supernatant;
C. transferring the supernatant liquid in the step B into a centrifugal tube by using a liquid transfer gun, drying by using nitrogen, adding a methanol aqueous solution, mixing in a vortex oscillation mode, and then carrying out centrifugal separation operation to obtain a supernatant liquid, wherein the obtained supernatant liquid is a sample to be detected;
and 5: determination of samples
D. Drawing of standard curve
Firstly, mixing standard working solutions with different concentrations in the step 1 with blank plasma of a normal person to prepare standard working blood, processing according to the step 4, detecting the obtained standard curve sample to obtain docetaxel and an internal standard chromatogram of different standard curve samples, respectively obtaining a standard target peak area and an internal standard peak area in the chromatogram, taking the ratio of the standard target peak area to the internal standard peak area as a vertical coordinate y of a standard curve graph, taking the ratio of the blood concentration of a target substance to be detected in the plasma after the preparation of the standard working solution to the internal standard working solution concentration, namely the relative concentration of the docetaxel, as a horizontal coordinate x of the standard curve graph, performing linear regression on the detection data by a weighted least square method to obtain a standard curve equation of y-a x + b, and obtaining weight coefficients a and b;
E. determination of samples to be tested
And (3) detecting the sample to be detected in the step (C) by using a high performance liquid chromatography-tandem mass spectrometry analyzer to obtain a docetaxel and an internal standard chromatogram of the sample to be detected, obtaining the peak area of a target object to be detected and the peak area of an internal standard object in the chromatogram, calculating the ratio y of the peak area of the target object to be detected and the peak area of the internal standard object, and substituting the ratio y into a standard curve equation in the step (D) to calculate the relative concentration x of the docetaxel.
The conditions of the high performance liquid chromatography-tandem mass spectrometry are as follows: performing gradient elution by using a shell 120 EC-C18 chromatographic column (3.0 x 50mm, 2.7 μm), wherein the column temperature is 30 ℃, the mobile phase A is 1mmol/L ammonium formate water, the mobile phase B is pure acetonitrile, the flow rate is 0.4mL/min, the sample introduction amount is 5 μ L, and the analysis time is 3.5 min; the mass spectrum is measured by adopting an electrospray ion source and selecting a mass spectrum scanning mode of a multi-reaction detection mode under a positive ion ionization mode, wherein the docetaxel and internal standard docetaxel-D9 parent ions are 808.30 and 817.30 respectively, daughter ions are 527.1 and 227.2 respectively, and the retention time is 2.24 and 2.23min respectively.
2. The method of claim 1, wherein the concentration of docetaxel in human plasma is determined by: the preparation number of the standard working solution in the step 1 is 8.
3. The method of claim 2, wherein the concentration of docetaxel in human plasma is determined by: the 8 standard working solutions are docetaxel solutions with the concentrations of 40ng/mL, 100ng/mL, 200ng/mL, 500ng/mL, 1000ng/mL, 2000ng/mL, 10000ng/mL and 20000ng/mL respectively.
4. The method of claim 1, wherein the concentration of docetaxel in human plasma is determined by: the methanol aqueous solution in the step 1, the step 2 and the step 4C consists of methanol and water, and the mass ratio of the methanol aqueous solution to the water is 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911117108.8A CN111089915A (en) | 2019-11-15 | 2019-11-15 | Method for measuring concentration of docetaxel drug in human plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911117108.8A CN111089915A (en) | 2019-11-15 | 2019-11-15 | Method for measuring concentration of docetaxel drug in human plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111089915A true CN111089915A (en) | 2020-05-01 |
Family
ID=70394134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911117108.8A Pending CN111089915A (en) | 2019-11-15 | 2019-11-15 | Method for measuring concentration of docetaxel drug in human plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111089915A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101685083A (en) * | 2009-04-30 | 2010-03-31 | 贾正平 | Super fast liquid phase chromatography-tandem mass spectrometric method for determining hydroxypropyl-beta-cyclodextrin |
| CN102621325A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Kit for detecting concentration of docetaxel in blood |
| CN103454360A (en) * | 2013-10-10 | 2013-12-18 | 中国医学科学院肿瘤医院 | Ultrafiltration and UPLC-MS/MS (ultra-high performance liquid chromatography tandem mass spectrometry) method for measuring concentration of free docetaxel in human plasma |
| CN105424843A (en) * | 2016-01-05 | 2016-03-23 | 复旦大学附属肿瘤医院 | High-performance liquid chromatography-triple quadrupole mass spectrometry combination method for determining paclitaxel or paclitaxel |
| CN107064389A (en) * | 2017-04-26 | 2017-08-18 | 苏州海科医药技术有限公司 | The UPLC MS/MS detection methods of free paclitaxel in a kind of blood plasma |
-
2019
- 2019-11-15 CN CN201911117108.8A patent/CN111089915A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101685083A (en) * | 2009-04-30 | 2010-03-31 | 贾正平 | Super fast liquid phase chromatography-tandem mass spectrometric method for determining hydroxypropyl-beta-cyclodextrin |
| CN102621325A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Kit for detecting concentration of docetaxel in blood |
| CN103454360A (en) * | 2013-10-10 | 2013-12-18 | 中国医学科学院肿瘤医院 | Ultrafiltration and UPLC-MS/MS (ultra-high performance liquid chromatography tandem mass spectrometry) method for measuring concentration of free docetaxel in human plasma |
| CN105424843A (en) * | 2016-01-05 | 2016-03-23 | 复旦大学附属肿瘤医院 | High-performance liquid chromatography-triple quadrupole mass spectrometry combination method for determining paclitaxel or paclitaxel |
| CN107064389A (en) * | 2017-04-26 | 2017-08-18 | 苏州海科医药技术有限公司 | The UPLC MS/MS detection methods of free paclitaxel in a kind of blood plasma |
Non-Patent Citations (2)
| Title |
|---|
| （美）施耐德（SNYDER, L.R.）等: "《现代液相色谱技术导论 第3版》", 31 July 2012 * |
| A. KORT 等: ""Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry"", 《JOURNAL OF CHROMATOGRAPHY B》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111175394A (en) | Method for detecting plasma catecholamine and metabolites thereof by liquid chromatography-tandem mass spectrometry | |
| CN111077239A (en) | Method for determining drug concentration of aripiprazole, clozapine, chlorpromazine, risperidone and 9-OH risperidone in human serum | |
| CN108828077B (en) | Kit for simultaneously detecting capecitabine and metabolite thereof in blood plasma as well as detection method and application thereof | |
| CN107247093A (en) | The detection method of free metanephrine class material in urine | |
| CN106990185A (en) | It is a kind of at the same determine blood plasma in six kinds of tyrosine kinase inhibitor concentration method | |
| CN109358127A (en) | A kind of method of Irinotecan and its metabolite content in detection human plasma | |
| CN105784894B (en) | Pesticide residue detection method for traditional Chinese medicine | |
| CN114460188A (en) | Kit for detecting human plasma catecholamine intermediate metabolite and testing method | |
| CN109959739B (en) | Liquid analysis method for detecting catecholamine content in blood | |
| CN109115921A (en) | A kind of method that A Pa replaces Buddhist nun's drug concentration in measurement human plasma | |
| CN111089915A (en) | Method for measuring concentration of docetaxel drug in human plasma | |
| CN111912920A (en) | Method for detecting mycophenolic acid and metabolites thereof in plasma by ultra-high performance liquid chromatography tandem mass spectrometry technology | |
| CN115166080B (en) | Method for detecting impurity A and impurity B in ifosfamide bulk drug | |
| CN110887924A (en) | Method for simultaneously detecting contents of retinol and α -tocopherol in blood | |
| CN109115922A (en) | A kind of method of Raltitrexed drug concentration in measurement human plasma | |
| CN106908543A (en) | The detection method of Gefitinib content in a kind of human plasma | |
| CN111024872B (en) | Method for rapidly detecting 3-methylthio propanol in sesame-flavor liquor | |
| CN108469488A (en) | Detect the liquid phase chromatography analytical method of content of valproic acid in blood | |
| CN112005110B (en) | Analysis method and application of dalteparin sodium nitrite degradation product | |
| Wang et al. | Determination of anlotinib, a tyrosine kinase inhibitor, in rat plasma by UHPLC-MS/MS and its application to a pharmacokinetic study | |
| CN109298081B (en) | Method for determining impurity A biological sample in Cetilistat | |
| CN111413439A (en) | Method for determining metformin in blood plasma by rapid hydrophilic interaction chromatography-tandem mass spectrometry | |
| CN111579690A (en) | Mass spectrum detection reagent for determining mycophenolic acid content in biological sample by using mycophenolic acid-D3 as internal standard substance and using method thereof | |
| CN114755326B (en) | Detection method of difenoconazole in hydroxypropyl methylcellulose | |
| CN115078621B (en) | Method for measuring concentration of irinotecan derivative Dxd in blood plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200501 |